FDA approves first treatment for pediatric functional constipation

Disease or Condition

Functional constipation is a common condition experienced by children and adolescents in which patients have infrequent bowel movements with hard stools that can be difficult or painful to pass. There is no known underlying organic cause and there are typically multiple contributing factors.

Efficacy

The efficacy of Linzess for the treatment of functional constipation in pediatric patients 6 to 17 years of age was established in a 12-week double-blind, placebo-controlled, randomized, multicenter clinical trial (Trial 7; NCT04026113) and supported by efficacy data from adequate and well-controlled trials in adults with chronic idiopathic constipation (constipation that persists and isn’t connected to an underlying illness).

For enrollment in the pediatric clinical trial, Rome III diagnostic criteria for functional constipation were modified to require that patients have less than three spontaneous bowel movements (SBMs) per week (defined as a BM that occurred in the absence of laxative, enema, or suppository use on the calendar day of or before the BM) and one or more of the following criteria at least once per week for at least two months before the screening visit:

• History of stool withholding or excessive voluntary stool retention

• History of painful or hard bowel movements (BMs)

• History of large diameter stools that may obstruct the toilet

• Presence of a large fecal mass in the rectum

• At least one episode of fecal incontinence per week

The primary efficacy endpoint was a 12-week change from baseline in SBM frequency rate. Patients who received Linzess experienced a greater improvement in the average number of SBMs per week than patients who received placebo. SBM frequency improved during week one and was maintained throughout the remainder of the 12-week treatment period.

Safety

The most common adverse reaction reported in pediatric patients 6 to 17 years of age with functional constipation is diarrhea. If severe diarrhea occurs, patients should stop receiving Linzess and be rehydrated. Linzess contains a boxed warning that the medication should not be taken by patients less than 2 years of age. In neonatal mice, linaclotide caused deaths due to dehydration. Patients with known or suspected mechanical gastrointestinal obstruction (bowel blockage) should not take Linzess. See full prescribing information for additional information on risks associated with Linzess.